跳至主要内容
临床试验/NCT05207852
NCT05207852招募中不适用

Clinical Pharmacology of Dexamethasone in Pregnant Women With Preterm Labor

Dongyang Liu1 个研究点 分布在 1 个国家目标入组 288 人开始时间: 2021年12月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
288
试验地点
1
主要终点
hypoglycemia

研究概览

简要总结

This study through to the pregnant woman blood concentrations of dexamethasone therapy after research, explore the pharmacokinetic data of dexamethasone in pregnant women, Chinese pregnant women dexamethasone pharmacokinetic model, provide a reference for the clinical use of dexamethasone dose, through the biomarkers of dexamethasone to promote fetal lung maturity and other metabolomics, It provides the basis for the effectiveness and safety study of dexamethasone.

详细描述

This study was a single-center, open clinical study. Maternal blood, feces, umbilical venous blood, and placental tissue were collected from GW24-36 Chinese women with preterm labor treated with dexamethasone, excluding placental abruption, severe intrauterine bleeding, or women who met the exclusion criteria. The determination and implementation of dexamethasone treatment by clinicians are executed according to the guidelines, the sample collected in addition to collecting feces and an active medication before an initiative to collect blood after medication, the other is to pregnant women normal diagnosis and treatment after operation opportunity or placental blood collection way, this study does not interfere with the normal of maternal pregnancy, production, and diagnosis and treatment process. A total of 288 Chinese pregnant women with preterm preterm birth who required dexamethasone treatment were randomly divided into eight groups with 36 participants in each group. At admission, blood was retained for each group after biochemical or routine blood test and blood was abandoned once (2 mL). After that, subjects were treated with DEX (5 mg intramuscularization, Q12h, for 2 days, if there was still no delivery 7 days after the first drug administration, another course of treatment or treatment as prescribed by the doctor). During the study period, do not take any food or drugs (such as coffee, alcohol, hypoglycemic drugs and other drugs used with caution or prohibited by pregnant women) that may affect the safety of the fetus. 2 mL of venous blood was collected from each group at 0.5 h, 2 h, 4 h, 6 h, 12 h, 24 h, 36 h, 48 h after the first administration. Blood biochemical or blood routine waste blood at the last prenatal examination was collected in each group, and umbilical venous blood was collected postpartum. Placenta samples were collected postpartum. All samples will be tested for dexamethasone and its metabolite concentrations, pharmacodynamics and safety indicators, hormones and metabolomics. Neonatal development was evaluated by PEABODY score and Bailey Scale at 6 and 24 months postnatal.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Prospective

入排标准

年龄范围
20 Years 至 40 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Aged 20-40 (inclusive);
  • Body mass Index (BMI) 18.5-27.9kg /m2 (inclusive)
  • Single and twin pregnancy;
  • Premature delivery at 24-36 weeks;
  • No antibiotics, prebiotics or probiotics were used one month before feces collection (such as Bifidobacterium triplex live powder, Lactobacillus acidophilus tablet, compound Lactobacillus acidophilus tablet, Bacillus subtilis diplex live intestinal capsule, etc.);
  • Preeclampsia patients accounted for about 1/10 of each group;
  • Use dexamethasone I.M. 5mg Q12h regimen (or other dexamethasone administration regimen) to promote fetal lung maturation.

排除标准

  • Ectopic pregnancy;
  • Suffering from diabetes, fetal distress, serious infectious diseases (such as sepsis, septic shock), fever;
  • Those who have taken glucocorticoid drugs within 2 weeks before joining the clinical trial;
  • Those who took clindamycin during the study period;
  • Congenital fetal malformation or fetal hypoxia in early pregnancy;
  • Convulsive patients;
  • HIV/HCV/ HEPATITIS A, drug abuse history;
  • Suffering from chorioamnitis, endometritis;
  • Placental abruption, severe intrauterine bleeding;
  • Pregnant women whose cervical dilation is greater than or equal to 4 cm or whose cervical length is less than or equal to 20 mm by ultrasound examination;
  • Pregnant women who took food or drugs during the study that might affect the safety of the fetus;
  • Pregnant women participating in other clinical trials.

结局指标

主要结局

hypoglycemia

时间窗: Within 24 hours of birth

Record fetal blood glucose (hypoglycemia within 1 hour, 3 hours, 6 hours, 24 hours after birth)

PEABODY

时间窗: Two years

Evaluate the mental and physical development of the newborn, including 2, 1 and 0, of which 2 is the best and 0 is the worst.

BayleyScales of Infant and Toddler Development

时间窗: Two years

Evaluate the mental and physical development of the newborn. Each infant's score on the Mental and motor scales was converted by age group into a standard score with an average of 100 and a standard deviation of 16, The Mental Development Index and Psychomotor Development Index were calculated.

Respiratory distress syndrome

时间窗: At birth

Whether respiratory distress syndrome occurs

次要结局

未报告次要终点

研究者

发起方
Dongyang Liu
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Dongyang Liu

Vice director of Drug Clinical Trial Center

Peking University Third Hospital

研究点 (1)

Loading locations...

相似试验